BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/6/2016 3:43:00 PM | Browse: 596 | Download: 303
Publication Name World Journal of Gastroenterology
Manuscript ID 28841
Country of Manuscript Source Greece
Received
2016-07-18 08:19
Peer-Review Started
2016-07-21 08:30
To Make the First Decision
2016-08-29 09:18
Return for Revision
2016-08-29 09:57
Revised
2016-08-31 23:09
Second Decision
2016-09-21 17:52
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2016-09-28 19:23
Articles in Press
2016-09-28 19:24
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2016-10-28 13:58
Publish the Manuscript Online
2016-11-06 15:43
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Editorial
Article Title Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
Manuscript Source Invited Manuscript
All Author List Evangelia Makri, Evangelos Cholongitas and Konstantinos Tziomalos
Funding Agency and Grant Number
Corresponding author Evangelos Cholongitas, MD, PhD, Assistant Professor of Internal Medicine, Fourth Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, 49 Konstantinoupoleos street, 54642 Thessaloniki, Greece. cholongitas@yahoo.gr
Keywords Nonalcoholic fatty liver disease; Obeticholic acid; Farnesoid X receptors; Insulin resistance; Fibrosis; Dyslipidemia; Steatosis; Hepatocellular cancer
Core Tip Nonalcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease in Western coun-tries, can progress to cirrhosis and is associated with increased all-cause and cardiovascular disease mortality risk. Current pharmacological treatment of NAFLD has limited efficacy and therefore, there is a pressing need to develop more effective and safe agents for this common and life-threatening disease. Obeticholic acid (OCA), a selective agonist of the farnesoid X receptors, might be a useful agent in the management of NAFLD. In the Farnesoid X Receptor Ligand Obeticholic Acid in non-alcoholic steatohepatitis (NASH) Treatment (FLINT) trial in patients with NASH, OCA administration was associated with improvements in liver histology, while weight loss and reduction in blood pressure were also observed. Although its adverse effects on the lipid profile and insulin sensitivity are worrisome, given the increased cardiovascular risk of this population, OCA might be considered in selected patients with NAFLD/NASH, particularly in those with adequately controlled glucose and lipid levels.
Publish Date 2016-11-06 15:43
Citation Makri E, Cholongitas E, Tziomalos K. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. World J Gastroenterol 2016; 22(41): 9039-9043
Url http://www.wjgnet.com/1007-9327/full/v22/i41/9039.htm
DOI http://dx.doi.org/10.3748/wjg.v22.i41.9039
Full Article (PDF) WJG-22-9039.pdf
Full Article (Word) WJG-22-9039.doc
Manuscript File 28841-Review.docx
Answering Reviewers 28841-Answering reviewers.pdf
Audio Core Tip 28841-Audio core tip.wma
Conflict-of-Interest Disclosure Form 28841-Conflict-of-interest statement.pdf
Copyright License Agreement 28841-Copyright assignment.pdf
Peer-review Report 28841-Peer-review(s).pdf
Scientific Misconduct Check 28841-Scientific misconduct check.pdf
Scientific Editor Work List 28841-Scientific editor work list.pdf